Tarsus Pharmaceuticals

TARSNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$2.788 B

$64.79 -0.83%

Close of 7 Aug 2026

Revenue

$451.4M

#1965 by revenue

Earnings

-$66.0M

Loss-making

Shares outstanding

43,882,996

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#28Beam TherapeuticsBEAM$2.84B
#29Iovance BiotherapeuticsIOVA$2.83B
#30Tarsus PharmaceuticalsTARS$2.79B
#31Biocryst PharmaceuticalsBCRX$2.40B
#32Hemab TherapeuticsCOAG$2.32B

Where these numbers come from

Share counts and financials for Tarsus Pharmaceuticals are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.